 CARLSBAD, Calif., March 30, 2021 GLOBE NEWSWIRE -- Design Therapeutics, Inc. Nasdaq: DSGN Design, a biotechnology company developing a platform of gene targeted chimera GeneTACTM small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, today announced the closing of its previously announced initial public offering of 13,800,000 shares of its common stock, which includes 1,800,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of 20.00 per share. Including the option exercise, the aggregate gross proceeds to Design from the offering were approximately 276.0 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market on March 26, 2021, under the ticker symbol DSGN. 